PubMed2004
Patients with arginine-vasopressin (AVP) deficiency have been reported to have a decreased bone mass. The mechanism behind this is not known. In this study, the effects of AVP on primary human osteoblast-like (hOB) cells and SaOS-2 cells were investigated. Cell proliferation was measured by [3H]thymidine incorporation or a commercially available kit (EZ4U), and protein synthesis by [3H]proline incorporation. In addition, the production of interleukin-6 (IL-6) and macrophage colony-stimulating factor (M-CSF) in hOB cells was determined. AVP at 10-100 pmol/l increased cell proliferation in hOB and SaOS-2 cells (p < 0.05). Protein synthesis increased in SaOS-2 cells incubated with 10-100 pmol/l AVP (p < 0.01). When hOB and SaOS-2 cells were incubated with AVP together with a vasopressin receptor-1 (V1)-antagonist ([beta-Mercapto-beta,beta-cyclopenta-methylenepropionyl1,O-Me-Tyr2,Arg8]-vasopressin) or a protein kinase C (PKC)-inhibitor (chelerythrine) the increase in cell proliferation in response to AVP was abolished. The production of IL-6 and M-CSF was decreased in hOB-cells incubated with 10 pmol/l AVP (p < 0.01). In addition, by RT-PCR, we found evidence for expression of mRNA for the vasopressin 1a (V1a)-receptor in hOB cells. In conclusion, AVP stimulated proliferation of hOB- and SaOS-2 cells. We suggest that the effect was mediated through the V1-receptor. Additionally, AVP decreased production of IL-6 and M-CSF from the hOB cells. Moreover, the V1a-receptor seems to be expressed in hOB cells.